New York 2025 Session Status: Introduced

A1248 — Prohibits the sale, offer for sale, or delivery of xylazine

Last action — In Senate Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Assembly. Introduced January 09, 2025. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Prohibits the knowing sale, offer for sale, or delivery of xylazine to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

Bill Text

Action History

  1. REFERRED TO CONSUMER PROTECTION

  2. DELIVERED TO SENATE

  3. PASSED ASSEMBLY

  4. AMENDED ON THIRD READING (T) 1248C

  5. ORDERED TO THIRD READING CAL.44

  6. RETURNED TO ASSEMBLY

  7. DIED IN SENATE

  8. RECOMMITTED TO CONSUMER PROTECTION

  9. RETURNED TO SENATE

  10. REPASSED ASSEMBLY

  11. AMENDED ON THIRD READING 1248B

  12. VOTE RECONSIDERED - RESTORED TO THIRD READING

  13. RETURNED TO ASSEMBLY

  14. RECALLED FROM SENATE

  15. REFERRED TO COMMERCE, ECONOMIC DEVELOPMENT AND SMALL BUSINESS

  16. DELIVERED TO SENATE

  17. PASSED ASSEMBLY

  18. ORDERED TO THIRD READING RULES CAL.202

  19. RULES REPORT CAL.202

  20. REPORTED

  21. REPORTED REFERRED TO RULES

  22. PRINT NUMBER 1248A

  23. AMEND (T) AND RECOMMIT TO WAYS AND MEANS

  24. REPORTED REFERRED TO WAYS AND MEANS

  25. REPORTED REFERRED TO CODES

  26. REFERRED TO CONSUMER AFFAIRS AND PROTECTION

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does A1248 do?
Prohibits the knowing sale, offer for sale, or delivery of xylazine to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.
Who sponsors A1248?
A1248 is sponsored by Yudelka Tapia.
What is the current status of A1248?
This bill has been introduced in the Assembly. Introduced January 09, 2025. It must pass committee before a floor vote.
Where can I track A1248?
Track A1248 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on A1248

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of A1248

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →